Shareholders Approve Capital Band Allowing Over 40% Potential Dilution
Summary
AC Immune shareholders approved a capital band that authorizes the Board to increase share capital by over 40% of current outstanding shares, providing significant financing flexibility but also substantial potential dilution.
Key Events
-
Capital Band Approved
Shareholders approved the introduction of a capital band, authorizing the Board to increase the company's share capital by up to 41.1 million shares (equivalent to over 40% of current outstanding shares) until June 11, 2031. This provides significant flexibility for future capital raises.
-
Employee Share Capital Increased
The conditional share capital for employee benefit plans was increased from CHF 86,683.80 to CHF 150,000.00, allowing for the issuance of up to 7.5 million shares for employee incentives.
-
2025 Financials and Compensation Endorsed
The 2025 IFRS Consolidated Financial Statements, Statutory Financial Statements, and Compensation Report were approved/endorsed, along with the discharge of the Board and Executive Management for 2025. The net loss for 2025 of CHF 67,595K increased accumulated losses to CHF 424,441K.
Analysis
Shareholders have approved a new capital band, granting the Board of Directors authorization to increase the company's share capital by up to 41.1 million shares until June 2031. This represents a potential dilution of over 40% of the current outstanding shares. While this provides AC Immune with significant flexibility for future capital raises, it also creates a substantial overhang for existing shareholders due to the potential for future dilution. This approval finalizes a proposal that was previously disclosed on May 15, 2026.
At the time of this filing, ACIU was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $230M. The 52-week trading range was $1.65 to $4.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.